MRIdian MR-Guided Radiotherapy: Treating Tumors You Can See in Real Time

Halfway through her session, the patient in the abdominal-cancer bay is playing what looks like the world’s slowest video game. On a small monitor above her, a white outline rises and falls with her breath. Her job: hold that outline inside a colored boundary. When she succeeds, the beam turns on. When her breathing pushes it out, the machine simply waits.

That outline is her tumor. Not a proxy for it, not a gold marker implanted near it, not a memory of where it sat on last week’s scan — the tumor itself, imaged live, several times per second.

For most of radiotherapy’s history, clinicians aimed at soft-tissue targets they could not actually see during treatment. Machines like the MRIdian were built to close that gap, and the engineering, evidence, and honest limitations behind them deserve a closer look.

What is MRIdian, exactly — and why do people call it an MR-linac?

MRIdian is a hybrid: one half is a magnetic resonance imaging scanner, the other half a linear accelerator, the standard workhorse machine that generates high-energy X-ray beams for cancer treatment. Bolt the two together and you get what the field calls an MR-linac — a device that images and treats at the same time. The MRIdian linac, developed by the company ViewRay, was among the first of these hybrids to reach patients.

The concept debuted clinically in 2014 in an early version that used radioactive cobalt sources for the treatment beam. In 2017, U.S. regulators cleared the modern configuration, which replaced cobalt with a compact linear accelerator mounted on a ring around a 0.35 tesla magnet. That pairing is the machine most centers use today.

The broader technique is called MR-guided radiotherapy, and the name is precise: magnetic resonance images guide where, when, and whether the radiation beam fires. Conventional machines also use image guidance, usually a quick cone-beam CT scan taken before the beam turns on. The difference is timing and detail. A pre-treatment CT is a snapshot; MR guidance is a live feed, and one that shows soft tissue — pancreas, bowel, prostate, liver — with a clarity CT cannot match. Whether that difference translates into better results for a given patient depends on the tumor, and the honest answer varies by site, as the evidence sections below spell out.

How can an MRI scanner and a radiation beam share one machine?

With difficulty. Engineers spent roughly two decades on this problem, because MRI scanners and linear accelerators are natural enemies. A linac works by accelerating electrons, and magnetic fields bend the paths of moving electrons — exactly what you do not want happening inside your treatment beam. Meanwhile, a linac’s electronics spray out radiofrequency noise that can wreck the faint signals an MRI listens for.

The MRIdian’s designers solved this with two main choices. First, the magnet is split into a so-called double-donut: two ring-shaped halves with a gap between them, so the treatment beam can pass through to the patient without punching through dense magnet hardware. Second, the field strength is deliberately low — 0.35 tesla, compared with the 1.5 or 3 tesla of a typical diagnostic scanner. A weaker field disturbs the radiation dose pattern less, particularly at air–tissue boundaries in the lungs and bowel, and it is easier to shield the accelerator from.

Low field sounds like a compromise, and in one sense it is: the images are not as crisp as a hospital’s diagnostic MRI. But for this job they do not need to be. The task is tracking a known target’s position and shape in real time, not hunting for a subtle lesion no one has found yet. Peer-reviewed technical descriptions of the 0.35 tesla design, published in the radiation oncology literature, describe imaging that is fully adequate for outlining tumors and the organs around them.

Why does seeing the tumor in real time matter so much?

Because tumors do not hold still. A pancreatic tumor can slide a centimeter or more with every breath. The prostate shifts as the bladder fills and the rectum changes shape. Liver lesions ride up and down on the diaphragm like a boat on swells. Radiotherapy plans have always had to account for this, and the traditional accounting method is blunt: draw a safety margin of extra tissue around the target and irradiate the whole envelope, so the tumor never escapes the beam.

Margins work, but they cost healthy tissue. Around a pancreatic tumor, that margin may contain stomach and small bowel — organs that tolerate radiation poorly. This is a key reason clinicians have historically had to hold back on treatment intensity for tumors in the upper abdomen: the risk to neighbors capped what the target could receive.

Live MR guidance attacks the problem from both ends. Watching the tumor continuously means the margin can shrink, often to just a few millimeters, because the machine no longer has to guess where the target might be. And because MRI shows the stomach, duodenum, and bowel directly, the team can see exactly where those vulnerable structures sit today — not where they sat on the planning scan two weeks ago. Smaller margins plus visible boundaries is the mechanism behind nearly every claimed advantage of mr guided radiotherapy, so it is worth understanding before evaluating any of the clinical results.

What happens when the tumor moves mid-beam? Automatic gating, explained

The machine stops itself. During treatment, the MRIdian acquires a continuous cine MRI — a moving picture at several frames per second — and software tracks the target’s outline in every frame. The team defines a boundary around the planned position, typically a few millimeters wide. If the tracked target slips outside that boundary, the beam holds automatically, in a fraction of a second, without anyone touching a button. When the target returns, the beam resumes.

This is called gating, and versions of it exist on conventional machines too. The usual approach relies on surrogates: implanted metal markers seen on X-ray, or an external sensor watching the rise and fall of the chest. Both assume the surrogate faithfully reports the tumor’s position, which is often true and sometimes not. MR-based gating removes the middleman — the thing being tracked is the tumor.

Patients are frequently recruited as partners in this process. Many centers show the live image on an in-bore monitor and coach the patient to hold a breath when the target sits inside the boundary. People tend to get remarkably good at it within a session or two; therapists sometimes describe it as the one part of cancer treatment where the patient can actively steer.

Two practical wins follow. No implanted fiducial markers are needed for many tumor types, sparing a needle procedure. And because MRI involves no ionizing radiation, all that continuous imaging adds zero extra radiation exposure — something no X-ray-based tracking system can claim.

What is on-table adaptive radiotherapy, and why is it MRIdian’s signature feature?

Anatomy changes daily. A loop of bowel that sat safely two centimeters from a pancreatic tumor on planning day can drape itself directly against the target a week later. Bladders fill differently. Tumors shrink. A treatment plan optimized for one day’s anatomy may be subtly — or seriously — wrong for another’s.

On-table adaptation is the answer, and it works like this. The patient lies on the table while the day’s MRI is acquired. The clinical team compares today’s anatomy with the plan. If things have shifted meaningfully, a physician re-outlines the relevant organs on the fresh images, software re-optimizes the beam arrangement, and a physicist runs an independent quality check — all while the patient waits, usually adding 20 to 40 minutes to the session. Then the new plan, tailored to that morning’s bowel and stomach positions, is delivered.

This matters most where the stakes of a shifted organ are highest. In the upper abdomen, adaptation is often the difference between delivering the full intended treatment and dialing it back to protect a wandering piece of bowel. Published early-phase studies of MR-guided adaptive treatment for pancreatic cancer were built entirely around this capability.

Worth stating plainly: adaptation is labor-intensive. It requires a physician, physicist, and therapists engaged at the machine for every adapted session, which is part of why MR-guided treatment slots are longer and scarcer than conventional ones. Centers reserve it for the cases where the payoff is clearest.

What is MR-Linac radiation therapy used for?

The technology earns its keep on soft-tissue tumors that move, deform, or press against radiation-sensitive neighbors. In practice, the most common applications include:

• Pancreatic cancer — arguably the flagship use, because the tumor moves with breathing and sits against stomach and duodenum.
• Liver tumors — both primary liver cancers and metastases, which ride the diaphragm and can be hard to see on CT without injected contrast.
• Prostate cancer — where soft-tissue visibility allows tighter margins around an organ bordered by bladder and rectum.
• Adrenal and kidney tumors — mobile targets tucked among bowel, liver, and spleen.
• Certain lung tumors — especially centrally located ones near the airways and heart.
• Oligometastatic disease — a limited number of metastases, often in abdominal lymph nodes, treated with focused high-precision courses.

Notice what is not on the list. Breast cancer, many head-and-neck cancers, bone metastases, and brain tumors are generally treated very well on conventional machines, where the target either does not move much or is anchored to visible bone. For those patients, an MR-linac would add time and complexity without a clear mechanism for benefit. Good radiation oncology is about matching the tool to the problem, and no reputable center treats everything on its most elaborate machine. If your tumor is in the abdomen or pelvis and moves with breathing, it is fair to ask whether MR guidance could help; if it is elsewhere, the standard approach is usually standard for good reason.

What does a MRIdian treatment session actually feel like?

Longer than conventional radiotherapy, quieter than chemotherapy, and stranger than either — in a mostly pleasant way. Before anything else comes MRI safety screening: staff will ask about pacemakers, implants, metal fragments, and anything else a strong magnet cares about, the same checklist used for a diagnostic scan.

On treatment day, you lie on the table, often with a lightweight imaging coil placed over the treatment area. The bore is noisier than a regular linac — MRI scanners knock and buzz — so earplugs or headphones are routine. The initial scan takes a few minutes; if the team adapts the plan, you rest while they work. Total table time for a MRIdian treatment commonly runs 45 to 90 minutes, versus roughly 15 for a conventional session.

Then comes the part patients tend to remember. If your tumor moves with breathing, you will likely watch it on a monitor and use breath-holds to keep it inside the target boundary, with the beam switching on only when you succeed. The radiation itself is silent and painless — you feel nothing when the beam fires.

Course lengths mirror modern practice elsewhere: many MR-guided treatments use stereotactic schedules of around five sessions rather than the five-to-eight-week courses of earlier eras, precisely because tighter targeting supports fewer, more intense visits. Your own schedule depends on your diagnosis, and only your treatment team can say what applies to you.

Is MRI radiation therapy? Clearing up a common confusion

No — and the distinction matters. Magnetic resonance imaging uses a strong magnetic field and radio waves to make pictures of the body. It involves no ionizing radiation at all, which is why, according to Mayo Clinic and other mainstream sources, MRI scans do not carry the radiation exposure associated with X-rays or CT.

Radiation therapy is a different technology entirely: high-energy X-ray beams (or sometimes particles) engineered to damage the DNA of cancer cells so they lose the ability to divide. It is delivered by a linear accelerator, and it absolutely does involve ionizing radiation — that is the whole point.

The MRIdian contains both. The MRI half is the eyes; the linac half is the treatment. When people search ‘is MRI radiation therapy,’ they are usually tangling these two components together, and the confusion is understandable given that one machine now houses both.

A useful consequence of the split: all the imaging done during MR-guided treatment — the daily setup scans, the continuous real-time tracking, potentially hours of imaging across a full course — adds nothing to the patient’s radiation exposure. On conventional machines, daily cone-beam CT scans each add a small imaging exposure. It is modest and clinically justified, but it is not zero. With MR guidance, the only radiation delivered is the radiation prescribed to treat the tumor, which is a genuinely clean piece of engineering logic.

What does the evidence actually show — and what doesn’t it show yet?

Here is the honest ledger. On the well-established side: MR-guided radiotherapy is feasible, safe, and delivers what it promises mechanically — real-time tracking, automated gating, and daily adaptation all work as designed, documented across peer-reviewed technical and clinical literature.

On short-term side effects, the strongest single piece of evidence comes from prostate cancer. A randomized trial comparing MRI-guided against CT-guided stereotactic prostate treatment found that MRI guidance — which allowed margins to shrink from four millimeters to two — produced meaningfully fewer moderate short-term urinary and bowel side effects. That is exactly the outcome the margin-reduction mechanism predicts, which strengthens confidence in the finding.

In pancreatic cancer, a multi-institutional phase 2 study of MR-guided adaptive stereotactic treatment reported that intensive, ablative-style courses could be delivered with low rates of severe gastrointestinal harm — notable because such intensity was historically considered too risky for this location. Encouraging, but a phase 2 study measures safety and feasibility, not proof of longer survival.

And that is the honest gap: no large randomized trial has yet shown that MR-guided treatment helps patients live longer than well-executed conventional radiotherapy for any tumor site. Trials pursuing that question are underway. What can be said today, carefully, is that the technology demonstrably reduces the amount of healthy tissue irradiated and, in at least one randomized setting, reduced short-term side effects. Anyone — vendor, hospital, or headline — claiming more than that is running ahead of the data.

MRIdian vs conventional image-guided radiotherapy: how do they compare?

Both approaches deliver modern, precise radiotherapy, and for many tumors the conventional route remains the right one. The differences cluster around what the machine can see and when it can react.

Feature	MRIdian (MR-guided)	Conventional (CT-guided)
Imaging during beam-on	Continuous live MRI, several frames per second	None, or intermittent X-ray checks
Soft-tissue detail	High — tumor and organs directly visible	Limited — bones clear, soft tissue often faint
Added imaging radiation	None (MRI is radiation-free)	Small daily exposure from cone-beam CT
Implanted markers	Usually unnecessary	Often required for moving targets
Automatic beam gating on the tumor itself	Yes	Typically via surrogates, if at all
Same-day plan adaptation	Routine, on the table	Rare; usually requires re-planning over days
Typical session length	45–90 minutes	10–20 minutes
Availability	Limited to specialized centers	Widespread

Read the table with the right question in mind — not ‘which machine is better’ but ‘does my tumor need what the left column offers.’ A bone metastasis gains nothing from live soft-tissue tracking. A pancreatic tumor wedged against the duodenum may gain a great deal. The comparison is a matching exercise, not a ranking.

Who might not be a good candidate for MR-guided treatment?

The magnet sets most of the rules. Because every session happens inside an MRI scanner, standard MRI exclusions apply: certain older pacemakers and defibrillators, some cochlear implants, specific aneurysm clips, and retained metal fragments can make the environment unsafe or the images unusable. Many modern cardiac devices are MR-conditional — safe under defined conditions — so a device is not an automatic disqualifier, but it requires careful review by the care team and often coordination with cardiology.

Claustrophobia deserves frank discussion. A conventional radiotherapy session means a few minutes under an open gantry; an MR-guided one means up to an hour or more inside a bore. Some patients manage well with coaching, music, or mild relaxation strategies arranged through their physician; for others, the confinement tips the balance toward a conventional machine. Body size can also matter, since the bore has fixed dimensions.

Then there is the largest category: patients whose tumors simply do not need this tool. If a target barely moves, sits far from sensitive organs, or is anchored to visible bone, conventional image-guided radiotherapy treats it excellently in a fraction of the time. Choosing the simpler machine in those cases is not a downgrade — it is good medicine.

Finally, breath-hold-based treatment asks something of the patient. People with severe lung disease who cannot hold a breath comfortably may need alternative motion-management strategies, which the team will assess before committing to a treatment approach.

Is ViewRay still in business? What patients should know

This question spikes in search data, and it stems from real events. In mid-2023, ViewRay, Inc. — the original developer of the MRIdian — filed for Chapter 11 bankruptcy protection. Its assets were subsequently purchased, and operations continued under a reorganized successor entity, ViewRay Systems, Inc., which supports the installed base of machines. Hospitals with ViewRay MRIdian systems have continued treating patients on them through and after the transition.

What does corporate turbulence mean for someone facing treatment? Less than the headlines might suggest. Your treatment is designed, checked, and delivered by your hospital’s radiation oncology team — physicians, physicists, dosimetrists, and therapists — operating under strict regulatory and quality frameworks that exist independently of any manufacturer’s balance sheet. Radiotherapy machines undergo daily, monthly, and annual quality-assurance testing by medical physicists regardless of who owns the company that built them.

That said, it is entirely reasonable to ask your center practical questions: Is the machine under an active service contract? What happens to my schedule if it needs maintenance? Is there a backup plan on a conventional machine if needed? Centers running these systems have answers to all three, because machine downtime contingencies are a routine part of radiation oncology operations everywhere, on every platform.

The wider field also extends beyond one company — MR-linac systems built around higher-field magnets exist as well, and the underlying technique of mr guided radiotherapy is an area of active investment and research across academic medicine.

How much does an MR-linac cost — and should that matter to you?

These are expensive machines. Industry and academic reports consistently place MR-linac systems at several times the price of a conventional linear accelerator, with all-in figures — machine, magnetic shielding, vault construction, and installation — commonly described in the range of several million to roughly ten million U.S. dollars. Staffing adds ongoing cost, since adaptive sessions occupy physicians and physicists at the machine in a way conventional treatment does not.

Why should a patient care about capital equipment economics? Two practical reasons. First, availability: the price tag concentrates these systems at larger academic and regional centers, so patients in many areas would need to travel for MR-guided treatment. Whether that travel is worthwhile depends entirely on whether the tumor stands to benefit — a conversation to have candidly with a radiation oncologist.

Second, billing — where there is reassuring news. In most healthcare systems, patients are not billed for the machine; they are billed for the radiotherapy procedure, and coverage is determined by the diagnosis and treatment type rather than the hardware brand. Insurance questions about a specific course of treatment should always go to the treating center’s financial counselors before treatment begins, since coverage details vary by plan and country.

A grounded way to think about it: the machine’s cost is the healthcare system’s problem to solve. Your questions are simpler — is MR guidance likely to help my specific tumor, is it accessible to me, and is it covered. Those three have knowable answers.

Side effects of MR-guided radiotherapy — and when to see a doctor

MR guidance changes how radiation is aimed, not what radiation is. So the possible side effects are the familiar ones of radiotherapy, shaped by the region treated. Fatigue is the near-universal companion, typically building over a course and easing in the weeks after. Abdominal treatment can bring nausea, reduced appetite, or loose stools. Pelvic treatment may cause urinary urgency, burning, or bowel irritation. Skin in the treated area can redden or feel tender. Mainstream references — MedlinePlus, the NHS, Mayo Clinic, and Cleveland Clinic — describe these patterns consistently, and most short-term effects settle within weeks.

The evidence discussed earlier suggests MR guidance can reduce some of these effects by shrinking the volume of healthy tissue exposed, and one randomized prostate trial bears that out for short-term urinary and bowel symptoms. Reduced is not eliminated, though, and every patient should know the warning signs that merit a prompt call.

Contact your care team the same day if you experience: fever above 100.4°F (38°C); vomiting that prevents you from keeping fluids down; blood in stool, urine, or vomit; severe or rapidly worsening pain; signs of dehydration such as dizziness or markedly reduced urination; or new shortness of breath. Radiation oncology departments expect and want these calls — teams routinely adjust supportive care mid-course, and early reporting makes that easier. Between visits, most centers schedule at least weekly clinician check-ins during treatment, and follow-up continues for months afterward to monitor recovery and response.

Frequently asked questions

Is MRI radiation therapy?

No. MRI uses a strong magnetic field and radio waves to create images and involves no ionizing radiation at all. Radiation therapy uses high-energy X-ray beams from a linear accelerator to damage cancer cells. The MRIdian combines both technologies in one machine: the MRI half provides the live pictures, and the linac half delivers the treatment. The imaging portion adds no radiation exposure whatsoever.

Is ViewRay still in business?

The original company, ViewRay, Inc., filed for Chapter 11 bankruptcy in mid-2023. Its assets were purchased, and operations continued under a successor entity, ViewRay Systems, Inc., which supports installed machines. Hospitals with MRIdian systems have continued treating patients throughout the transition. Your treatment quality is governed by your hospital’s radiation oncology team and regulatory quality-assurance requirements, which operate independently of any manufacturer’s corporate situation.

What is MR-Linac radiation therapy used for?

Mainly for soft-tissue tumors that move with breathing or sit near radiation-sensitive organs. The most common uses are pancreatic cancer, liver tumors, prostate cancer, adrenal and kidney tumors, certain centrally located lung tumors, and limited metastases in the abdomen. Tumors that barely move or sit far from vulnerable structures — many breast, bone, and brain targets — are usually treated just as well on conventional machines.

How much does an MR-linac cost?

Industry and academic reports typically describe all-in costs — machine, magnetic shielding, vault construction, and installation — ranging from several million to roughly ten million U.S. dollars, several times the price of a conventional linear accelerator. Patients are not billed for the machine itself; charges are based on the radiotherapy procedure and diagnosis. Coverage questions for a specific treatment course should go to the treating center’s financial counselors.

Does MRIdian treatment hurt?

The radiation itself is painless and silent — you feel nothing when the beam is on. What patients notice is the environment: the MRI bore is enclosed and noisy, so earplugs or headphones are standard, and sessions run longer than conventional radiotherapy, often 45 to 90 minutes. Some people find lying still that long uncomfortable or feel claustrophobic; care teams can help with positioning, coaching, and relaxation strategies.

How long does a MRIdian treatment session take?

Plan on 45 to 90 minutes on the table, compared with roughly 15 minutes for a conventional session. The extra time covers the daily setup MRI, on-table plan adaptation when today’s anatomy has shifted — which adds about 20 to 40 minutes — and breath-hold-gated delivery, where the beam fires only while the tumor sits inside its target boundary. Full courses often use around five sessions for stereotactic treatments.

Do I need implanted markers or fiducials with MRIdian?

Usually not, and that is one of the technology’s practical advantages. Conventional machines often require small metal markers implanted near a moving tumor so X-ray imaging can infer its position. Because the MRIdian sees the tumor directly on continuous MRI, most patients skip the marker-placement procedure entirely. Your radiation oncologist will confirm what your specific treatment plan requires, since practices vary by tumor site and center.

Can MRIdian treat pancreatic cancer?

Pancreatic cancer is one of its most studied applications. A multi-institutional phase 2 trial showed that intensive MR-guided adaptive stereotactic treatment could be delivered with low rates of severe gastrointestinal side effects — notable because the pancreas sits against the stomach and bowel, which historically limited treatment intensity. That study established safety and feasibility; larger randomized trials are still needed to determine effects on survival. Suitability is always an individual decision made with your oncology team.

Is a 0.35 tesla magnet strong enough for good images?

For this specific job, yes. The 0.35 tesla field is weaker than a diagnostic scanner’s 1.5 or 3 tesla, so images are less crisp — but the task is tracking a known target’s position several times per second, not detecting a subtle undiagnosed lesion. Peer-reviewed technical literature describes the low-field images as fully adequate for outlining tumors and neighboring organs, and the weaker field actually disturbs the radiation dose pattern less.

Can I have MR-guided radiotherapy if I have a pacemaker?

Sometimes. Every session happens inside an MRI environment, so standard MRI safety rules apply. Many modern cardiac devices are MR-conditional, meaning they are safe under defined conditions with proper precautions and cardiology coordination; certain older devices are not compatible. A pacemaker is not an automatic disqualifier, but it requires careful review by the care team, and some patients will be better served on a conventional machine.

References

• Radiation Therapy — MedlinePlus, National Library of Medicine
• Radiotherapy — NHS
• Radiation Therapy — Cleveland Clinic
• Technical design and concept of a 0.35 T MR-Linac — PMC, National Institutes of Health

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.